

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

MANAGEMENT REPORT

Management's Responsibility for Financial Reporting

The accompanying financial statements have been prepared by I.G. Investment Management, Ltd., as Manager of IG Mackenzie Global Health Care Fund (the "Fund"). The Manager is responsible for the integrity, objectivity and reliability of the data presented. This responsibility includes selecting appropriate accounting principles and making judgments and estimates consistent with IFRS Accounting Standards.

The Manager is also responsible for the development of internal controls over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors (the "Board") of I.G. Investment Management, Ltd. is responsible for reviewing and approving the financial statements and overseeing the Manager's performance of its financial reporting responsibilities. The Board meets regularly with the Manager, internal auditors and external auditors to discuss internal controls over the financial reporting process, auditing matters and financial reporting issues.

KPMG LLP is the external auditor of the Fund. It is appointed by the Board. The external auditor has audited the financial statements in accordance with Canadian generally accepted auditing standards to enable it to express to the securityholders its opinion on the financial statements. Its report is set out below.

On behalf of I.G. Investment Management, Ltd.,
Manager of the Fund



Damon Murchison
President and Chief Executive Officer



Terry Rountes
Chief Financial Officer, Funds

June 6, 2024

INDEPENDENT AUDITOR'S REPORT

To the Securityholders of IG Mackenzie Global Health Care Fund (the "Fund")

Opinion

We have audited the financial statements of the Fund, which comprise:

- the statements of financial position as at March 31, 2024 and March 31, 2023
- the statements of comprehensive income for the periods then ended as indicated in note 1
- the statements of changes in financial position for the periods then ended as indicated in note 1
- the statements of cash flows for the periods then ended as indicated in note 1 and
- notes to the financial statements, including a summary of material accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at March 31, 2024 and March 31, 2023, and its financial performance and cash flows for the periods then ended as indicated in note 1 in accordance with IFRS Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

INDEPENDENT AUDITOR'S REPORT (cont'd)

Other Information

Management is responsible for the other information. Other information comprises:

– the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the financial reporting process of the Fund.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



Chartered Professional Accountants
Winnipeg, Canada
June 6, 2024

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF FINANCIAL POSITION

at March 31 (in \$ 000 except per security amounts)

	2024	2023
	\$	\$
ASSETS		
Current assets		
Investments at fair value	330,896	319,520
Cash and cash equivalents	1,535	390
Dividends receivable	300	510
Accounts receivable for investments sold	–	–
Accounts receivable for securities issued	227	–
Taxes recoverable	184	256
Total assets	333,142	320,676
LIABILITIES		
Current liabilities		
Accounts payable for investments purchased	8	4
Accounts payable for securities redeemed	–	7
Due to manager	40	13
Total liabilities	48	24
Net assets attributable to securityholders	333,094	320,652

	Net assets attributable to securityholders (note 3)			
	per security		per series	
	2024	2023	2024	2023
Series A	42.35	37.63	25,575	28,376
Series B	41.69	37.04	17,080	16,950
Series F	29.70	26.15	276,929	258,738
Series J DSC	38.10	33.75	8,647	10,843
Series J NL	37.98	33.66	4,863	5,745
			333,094	320,652

STATEMENTS OF COMPREHENSIVE INCOME

for the periods ended March 31 (in \$ 000 except per security amounts)

	2024	2023
	\$	\$
Income		
Dividends	6,874	7,951
Interest income for distribution purposes	21	27
Other changes in fair value of investments and other net assets		
Net realized gain (loss)	68,339	5,761
Net unrealized gain (loss)	(27,400)	(570)
Securities lending income	1	14
Total income (loss)	47,835	13,183
Expenses (note 6)		
Management fees	3,669	3,911
Management fee rebates	(4)	–
Service fees	174	215
Administration fees	658	821
Interest charges	5	1
Trustee fees	152	–
Commissions and other portfolio transaction costs	472	252
Independent Review Committee fees	1	1
Other	–	1
Expenses before amounts absorbed by Manager	5,127	5,202
Expenses absorbed by Manager	–	–
Net expenses	5,127	5,202
Increase (decrease) in net assets attributable to securityholders from operations before tax	42,708	7,981
Foreign withholding tax expense (recovery)	1,052	1,090
Foreign income tax expense (recovery)	65	348
Increase (decrease) in net assets attributable to securityholders from operations	41,591	6,543

	Increase (decrease) in net assets attributable to securityholders from operations (note 3)			
	per security		per series	
	2024	2023	2024	2023
Series A	4.50	0.33	3,071	298
Series B	4.52	0.37	1,984	204
Series F	3.64	0.63	34,821	6,032
Series J DSC	4.01	0.08	1,088	30
Series J NL	4.15	(0.12)	627	(21)
			41,591	6,543

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CHANGES IN FINANCIAL POSITION

for the periods ended March 31 (in \$ 000 except per security amounts)

	Total		Series A		Series B		Series F	
	2024	2023	2024	2023	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS								
Beginning of period	320,652	323,834	28,376	40,061	16,950	22,904	258,738	241,097
Increase (decrease) in net assets from operations	41,591	6,543	3,071	298	1,984	204	34,821	6,032
Distributions paid to securityholders:								
Ordinary	(1,553)	(1,031)	–	–	–	–	(1,553)	(1,031)
Capital gains	–	(4,769)	–	(153)	–	(90)	–	(4,388)
Management fee rebates	(4)	–	–	–	–	–	–	–
Total distributions paid to securityholders	(1,557)	(5,800)	–	(153)	–	(90)	(1,553)	(5,419)
Security transactions:								
Proceeds from securities issued	35,643	53,882	223	352	2,508	2,762	32,333	47,058
Reinvested distributions	1,456	4,487	–	149	–	86	1,452	4,122
Payments on redemption of securities	(64,691)	(62,294)	(6,095)	(12,331)	(4,362)	(8,916)	(48,862)	(34,152)
Total security transactions	(27,592)	(3,925)	(5,872)	(11,830)	(1,854)	(6,068)	(15,077)	17,028
Increase (decrease) in net assets attributable to securityholders	12,442	(3,182)	(2,801)	(11,685)	130	(5,954)	18,191	17,641
End of period	333,094	320,652	25,575	28,376	17,080	16,950	276,929	258,738
Increase (decrease) in fund securities (in thousands) (note 7):								
Securities outstanding – beginning of period			754	1,069	458	621	9,893	9,239
Issued			6	9	65	76	1,177	1,800
Reinvested distributions			–	4	–	2	54	155
Redeemed			(156)	(328)	(113)	(241)	(1,801)	(1,301)
Securities outstanding – end of period			604	754	410	458	9,323	9,893

	Series J DSC		Series J NL	
	2024	2023	2024	2023
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS				
Beginning of period	10,843	13,897	5,745	5,875
Increase (decrease) in net assets from operations	1,088	30	627	(21)
Distributions paid to securityholders:				
Ordinary	–	–	–	–
Capital gains	–	(91)	–	(47)
Management fee rebates	(3)	–	(1)	–
Total distributions paid to securityholders	(3)	(91)	(1)	(47)
Security transactions:				
Proceeds from securities issued	37	1,730	542	1,980
Reinvested distributions	3	87	1	43
Payments on redemption of securities	(3,321)	(4,810)	(2,051)	(2,085)
Total security transactions	(3,281)	(2,993)	(1,508)	(62)
Increase (decrease) in net assets attributable to securityholders	(2,196)	(3,054)	(882)	(130)
End of period	8,647	10,843	4,863	5,745
Increase (decrease) in fund securities (in thousands) (note 7):				
Securities outstanding – beginning of period	321	413	171	175
Issued	1	48	15	57
Reinvested distributions	–	3	–	1
Redeemed	(95)	(143)	(58)	(62)
Securities outstanding – end of period	227	321	128	171

The accompanying notes are an integral part of these financial statements.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENTS OF CASH FLOWS

for the periods ended March 31 (in \$ 000)

	2024	2023
	\$	\$
Cash flows from operating activities		
Net increase (decrease) in net assets attributable to securityholders from operations	41,591	6,543
Adjustments for:		
Net realized loss (gain) on investments	(68,410)	(5,513)
Change in net unrealized loss (gain) on investments	27,400	570
Purchase of investments	(239,743)	(120,719)
Proceeds from sale and maturity of investments	269,379	128,506
(Increase) decrease in accounts receivable and other assets	282	36
Increase (decrease) in accounts payable and other liabilities	27	(2)
Net cash provided by (used in) operating activities	30,526	9,421
Cash flows from financing activities		
Proceeds from securities issued	31,301	35,297
Payments on redemption of securities	(60,583)	(43,702)
Distributions paid net of reinvestments	(101)	(1,313)
Net cash provided by (used in) financing activities	(29,383)	(9,718)
Net increase (decrease) in cash and cash equivalents	1,143	(297)
Cash and cash equivalents at beginning of period	390	674
Effect of exchange rate fluctuations on cash and cash equivalents	2	13
Cash and cash equivalents at end of period	1,535	390
Cash	1,535	390
Cash equivalents	–	–
Cash and cash equivalents at end of period	1,535	390
Supplementary disclosures on cash flow from operating activities:		
Dividends received	7,084	7,925
Foreign taxes paid	1,117	1,090
Income taxes paid	–	348
Interest received	21	27
Interest paid	5	1

The accompanying notes are an integral part of these financial statements.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS

as at March 31, 2024

	Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
EQUITIES					
Abbott Laboratories	United States	Health Care	38,873	5,717	5,984
AbbVie Inc.	United States	Health Care	68,379	13,405	16,863
Agilent Technologies Inc.	United States	Health Care	26,213	4,508	5,166
Align Technology Inc.	United States	Health Care	820	223	364
Amgen Inc.	United States	Health Care	25,158	7,687	9,687
AstraZeneca PLC	United Kingdom	Health Care	34,109	6,874	6,226
Avantor Inc.	United States	Health Care	9,618	264	333
Bausch Health Cos. Inc.	United States	Health Care	118,370	1,326	1,699
Baxter International Inc.	United States	Health Care	72,545	3,484	4,199
Becton, Dickinson and Co.	United States	Health Care	1,352	464	453
BioMerieux SA	France	Health Care	2,120	313	317
Boston Scientific Corp.	United States	Health Care	18,825	1,406	1,746
Bristol-Myers Squibb Co.	United States	Health Care	110,279	8,211	8,099
Cardinal Health Inc.	United States	Health Care	2,561	297	388
Carl Zeiss Meditec AG	Germany	Health Care	1,888	330	319
Cencora Inc.	United States	Health Care	15,372	4,120	5,059
Centene Corp.	United States	Health Care	47,049	4,253	5,001
Charles River Laboratories International Inc.	United States	Health Care	906	250	332
Chugai Pharmaceutical Co. Ltd.	Japan	Health Care	78,500	3,119	4,055
Cigna Corp.	United States	Health Care	16,861	5,833	8,293
Cochlear Ltd.	Australia	Health Care	1,091	253	325
Coloplast AS	Denmark	Health Care	1,775	285	324
CSL Ltd.	Australia	Health Care	5,165	1,376	1,313
CVS Health Corp.	United States	Health Care	72,250	6,736	7,804
Daiichi Sankyo Co. Ltd.	Japan	Health Care	7,400	319	316
Danaher Corp.	United States	Health Care	14,840	4,131	5,019
DaVita Inc.	United States	Health Care	2,744	361	513
Demant AS	Denmark	Health Care	4,638	326	312
Dentsply Sirona Inc.	United States	Health Care	7,286	372	327
DiaSorin SpA	Italy	Health Care	2,361	328	309
Edwards Lifesciences Corp.	United States	Health Care	2,783	281	360
Elevance Health Inc.	United States	Health Care	4,913	3,039	3,450
Eli Lilly and Co.	United States	Health Care	22,850	13,998	24,073
Embeceta Corp.	United States	Health Care	16,932	487	304
EssilorLuxottica	France	Health Care	2,687	788	823
Fresenius Medical Care AG & Co.	Germany	Health Care	6,005	365	313
Fresenius SE & Co. KGaA	Germany	Health Care	8,576	322	313
GE HealthCare Technologies Inc.	United States	Health Care	38,660	3,977	4,760
Getinge AB	Sweden	Health Care	12,487	330	340
Gilead Sciences Inc.	United States	Health Care	72,046	7,644	7,147
GSK PLC	United Kingdom	Health Care	241,796	6,844	7,062
HCA Holdings Inc.	United States	Health Care	760	313	343
Hikma Pharmaceuticals PLC	United Kingdom	Health Care	103,452	3,183	3,393
Hologic Inc.	United States	Health Care	3,270	355	345
Hoya Corp.	Japan	Health Care	29,200	4,590	4,896
Humana Inc.	United States	Health Care	10,075	5,442	4,731
IDEXX Laboratories Inc.	United States	Health Care	510	327	373
Incyte Corp.	United States	Health Care	46,780	3,646	3,609
InMode Ltd.	United States	Health Care	79,367	2,417	2,323
Insulet Corp.	United States	Health Care	1,430	363	332
Intuitive Surgical Inc.	United States	Health Care	6,458	2,800	3,490
Ipsen SA	France	Health Care	2,170	361	350
IQVIA Holdings Inc.	United States	Health Care	15,207	4,118	5,208
Jazz Pharmaceuticals PLC	United States	Health Care	2,030	326	331
Johnson & Johnson	United States	Health Care	90,154	19,435	19,313
McKesson Corp.	United States	Health Care	765	451	556
Medtronic PLC	United States	Health Care	69,675	8,130	8,223
Merck & Co. Inc.	United States	Health Care	64,564	10,072	11,537
Merck KGaA	Germany	Health Care	1,436	311	343
Molina Healthcare Inc.	United States	Health Care	623	239	347
Novartis AG Reg.	Switzerland	Health Care	47,287	6,419	6,205
Novo Nordisk AS B	Denmark	Health Care	86,373	9,834	14,910

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS (cont'd)

as at March 31, 2024

	Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
EQUITIES (cont'd)					
Ono Pharmaceutical Co. Ltd.	Japan	Health Care	82,200	2,105	1,805
Otsuka Holdings Co. Ltd.	Japan	Health Care	72,800	3,709	4,110
Pfizer Inc.	United States	Health Care	105,686	5,248	3,972
Recordati SpA	Italy	Health Care	5,598	355	419
Regeneron Pharmaceuticals Inc.	United States	Health Care	1,486	1,588	1,937
ResMed Inc.	United States	Health Care	1,380	362	370
Roche Holding AG Genussscheine	Switzerland	Health Care	33,907	13,532	11,698
Royalty Pharma PLC	United States	Health Care	8,300	319	341
Sanofi	United States	Health Care	16,230	2,205	2,157
Sartorius AG Pfd.	Germany	Health Care	638	330	344
Sartorius Stedim Biotech SA	France	Health Care	884	328	341
Shionogi & Co. Ltd.	Japan	Health Care	24,300	1,554	1,685
Sonova Holding AG	Switzerland	Health Care	7,247	3,039	2,842
Steris PLC	United States	Health Care	5,710	1,695	1,739
Stryker Corp.	United States	Health Care	13,580	5,210	6,582
Teleflex Inc.	United States	Health Care	11,124	3,190	3,407
Terumo Corp.	Japan	Health Care	12,000	241	293
Teva Pharmaceutical Industries Ltd. ADR	Israel	Health Care	66,400	1,082	1,269
Thermo Fisher Scientific Inc.	United States	Health Care	16,218	11,661	12,766
United Therapeutics Corp.	United States	Health Care	1,470	471	457
UnitedHealth Group Inc.	United States	Health Care	25,904	17,048	17,355
Universal Health Services Inc. Class B	United States	Health Care	8,497	1,731	2,100
Veralto Corp.	United States	Industrials	2,723	281	327
Vertex Pharmaceuticals Inc.	United States	Health Care	3,859	1,732	2,185
Viatis Inc.	United States	Health Care	231,015	2,928	3,736
Waters Corp.	United States	Health Care	688	245	321
West Pharmaceutical Services Inc.	United States	Health Care	676	339	362
Zimmer Biomet Holdings Inc.	United States	Health Care	1,940	330	347
Zoetis Inc.	United States	Health Care	4,692	1,142	1,075
Total equities				291,778	327,590
EXCHANGE-TRADED FUNDS					
Health Care Select Sector SPDR Fund	United States	Exchange-Traded Funds	16,525	3,129	3,306
Total exchange-traded funds				3,129	3,306
Transaction costs				(357)	—
Total investments				294,550	330,896
Cash and cash equivalents					1,535
Other assets less liabilities					663
Net assets attributable to securityholders					333,094

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SUMMARY OF INVESTMENT PORTFOLIO

MARCH 31, 2024

PORTFOLIO ALLOCATION	% OF NAV
Equities	98.3
Exchange-traded funds	1.0
Cash and cash equivalents	0.5
Other assets (liabilities)	0.2

REGIONAL ALLOCATION	% OF NAV
United States	76.0
Switzerland	6.2
Japan	5.2
United Kingdom	5.0
Denmark	4.7
France	0.5
Australia	0.5
Germany	0.5
Cash and cash equivalents	0.5
Israel	0.4
Italy	0.2
Other assets (liabilities)	0.2
Sweden	0.1

SECTOR ALLOCATION	% OF NAV
Pharmaceuticals	42.1
Health care equipment and supplies	17.1
Health care providers and services	17.0
Biotechnology	13.0
Life sciences tools and services	9.0
Exchange-traded funds	1.0
Cash and cash equivalents	0.5
Other assets (liabilities)	0.2
Commercial services and supplies	0.1

MARCH 31, 2023

PORTFOLIO ALLOCATION	% OF NAV
Equities	99.5
Exchange-traded funds	0.2
Other assets (liabilities)	0.2
Cash and cash equivalents	0.1

REGIONAL ALLOCATION	% OF NAV
United States	73.1
United Kingdom	5.1
Denmark	5.0
Switzerland	4.9
Japan	4.7
France	3.9
Australia	0.9
Finland	0.9
Germany	0.7
Sweden	0.3
Other assets (liabilities)	0.2
Cash and cash equivalents	0.1
Italy	0.1
Netherlands	0.1

SECTOR ALLOCATION	% OF NAV
Pharmaceuticals	41.6
Health care equipment and supplies	17.1
Health care providers and services	16.7
Biotechnology	13.7
Life sciences tools and services	10.4
Exchange-traded funds	0.2
Other assets (liabilities)	0.2
Cash and cash equivalents	0.1

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

1. Organization of the Fund, Fiscal Periods and General Information

(a) Organization of the Fund

The Fund is organized as an open-ended mutual fund trust established under the laws of Manitoba and governed by a Declaration of Trust. The address of the Fund's registered office is 447 Portage Avenue, Winnipeg, Manitoba, Canada. The Fund is authorized to issue an unlimited number of securities of multiple series. If issued, Series F, P, and S securities are only available for purchase by other IG Wealth Management Funds or other qualified investors. All series generally share in the operations of the Fund on a pro rata basis except for items that can be specifically attributed to one or more series. Distributions for each series may vary, partly due to the differences in expenses between the series.

The information provided in these financial statements and notes thereto is for the periods ended or as at March 31, 2024 and 2023, as applicable. In the year a Fund or series is established or reinstated, 'period' represents the period from inception or reinstatement. Where a series of a Fund was terminated during either period, the information for the series is provided up to close of business on the termination date.

(b) General information

I.G. Investment Management, Ltd. is the Manager and Trustee of the Fund. I.G. Investment Management, Ltd. and/or Mackenzie Investments Europe Limited acts as Portfolio Advisor(s) to the Fund. In some cases, Mackenzie Financial Corporation and/or Mackenzie Investments Asia Limited has been engaged as sub-advisor to provide investment services to the Fund. The Fund is distributed by Investors Group Financial Services Inc. and Investors Group Securities Inc. (collectively, the "Distributors"). These companies are, indirectly, wholly owned subsidiaries of IGM Financial Inc.

IGM Financial Inc. is a subsidiary of Power Corporation of Canada. Companies related to Power Corporation of Canada are therefore considered affiliates of the Trustee, the Manager and the Distributors. The Fund may invest in certain securities within the Power Group of Companies, subject to certain governance criteria, and these holdings, as at the end of the period, have been identified on the Schedule of Investments for the Fund. Any transactions during the periods, other than transactions with unlisted open-ended mutual funds, were executed through market intermediaries and under prevailing market terms and conditions.

2. Basis of Preparation and Presentation

These audited annual financial statements ("financial statements") have been prepared in accordance with IFRS Accounting Standards ("IFRS"). A summary of the Fund's material accounting policies under IFRS is presented in Note 3.

These financial statements are presented in Canadian dollars, which is the Fund's functional currency, and rounded to the nearest thousand unless otherwise indicated. These financial statements are prepared on a going concern basis using the historical cost basis, except for financial instruments that have been measured at fair value.

These financial statements were authorized for issue by the Manager on June 6, 2024.

3. Material Accounting Policies

The Fund adopted Disclosure of Accounting Policies Amendments to IAS 1 and IFRS Practice Statements 2 from April 1, 2023. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information disclosed in the financial statements. The amendments require the disclosure of 'material' rather than 'significant' accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies. The Manager reviewed the accounting policies and made updates to the information disclosed in certain instances in line with the amendments.

(a) Financial instruments

Financial instruments include financial assets and liabilities such as debt and equity securities, investment funds and derivatives. The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments* ("IFRS 9"). Upon initial recognition, financial instruments are classified as fair value through profit or loss ("FVTPL"). All financial assets and liabilities are recognized in the Statement of Financial Position when the Fund becomes a party to the contractual requirements of the instrument. Financial instruments are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation is discharged, cancelled and expires. Investment purchase and sale transactions are recorded as of the trade date.

Financial instruments are subsequently measured at FVTPL with changes in fair value recognized in the Statement of Comprehensive Income – Other changes in fair value of investments and other net assets – Net unrealized gain (loss). The cost of investments is determined on a weighted average cost basis.

Realized and unrealized gains and losses on investments are calculated based on the weighted average cost of investments and exclude commissions and other portfolio transaction costs, which are separately reported in the Statement of Comprehensive Income – Commissions and other portfolio transaction costs.

Gains and losses arising from changes in the fair value of the investments are included in the Statement of Comprehensive Income for the period in which they arise.

The Fund accounts for its holdings in unlisted open-ended investment funds, private funds ("Underlying Funds") and Exchange-Traded Funds ("ETFs"), if any, at FVTPL. For private funds, the Manager will rely on the valuations provided by the managers of the private funds, which represents the Fund's proportionate share of the net assets of these private funds. The Fund's investment in Underlying Funds and ETFs, if any, is presented in the Schedule of Investments at fair value which represents the Fund's maximum exposure on these investments.

The Fund's redeemable securities contain multiple dissimilar contractual obligations and entitle securityholders to the right to redeem their interest in the Fund for cash equal to their proportionate share of the net asset value of the Fund and therefore meet the criteria for classification as financial liabilities under IAS 32 *Financial Instruments: Presentation*. The Fund's obligation for net assets attributable to securityholders is presented at the redemption amount.

IAS 7, *Statement of Cash Flows*, requires disclosures related to changes in liabilities and assets, such as the securities of the Fund, arising from financing activities. Changes in securities of the Fund, including both changes from cash flows and non-cash changes, are included in the Statement of Changes in Financial Position.

Any changes in the securities not settled in cash as at the end of the period are presented as either Accounts receivable for securities issued or Accounts payable for securities redeemed in the Statement of Financial Position. These accounts receivable and accounts payable amounts typically settle shortly after period-end.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(b) Fair value measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Investments listed on a public securities exchange or traded on an over-the-counter market are valued on the basis of the last traded market price or closing price recorded by the security exchange on which the security is principally traded, where this price falls within the quoted bid-ask spread for the investment. In circumstances where this price is not within the bid-ask spread, Mackenzie determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Mutual fund securities of an underlying fund are valued on a business day at the price calculated by the manager of such underlying fund in accordance with the constating documents of such underlying fund. Unlisted or non-exchange traded investments, or investments where a last sale or close price is unavailable or investments for which market quotations are, in Mackenzie's opinion, inaccurate, unreliable, or not reflective of all available material information, are valued at their fair value as determined by Mackenzie using appropriate and accepted industry valuation techniques including valuation models. The fair value determined using valuation models requires the use of inputs and assumptions based on observable market data including volatility and other applicable rates or prices. In limited circumstances, the fair value may be determined using valuation techniques that are not supported by observable market data.

Cash and cash equivalents which includes cash on deposit with financial institutions and short-term investments that are readily convertible to cash, are subject to an insignificant risk of changes in value, and are used by the Fund in the management of short-term commitments. Cash and cash equivalents are reported at fair value which closely approximates their amortized cost due to their nature of being highly liquid and having short terms to maturity. Bank overdraft positions are presented under current liabilities as bank indebtedness in the Statement of Financial Position.

The Fund may use derivatives (such as written options, futures, forward contracts, swaps or customized derivatives) to hedge against losses caused by changes in securities prices, interest rates or exchange rates. The Fund may also use derivatives for non-hedging purposes in order to invest indirectly in securities or financial markets, to gain exposure to other currencies, to seek to generate additional income, and/or for any other purpose considered appropriate by the Fund's portfolio manager(s), provided that the use of the derivative is consistent with the Fund's investment objectives. Any use of derivatives will comply with Canadian mutual fund laws, subject to the regulatory exemptions granted to the Fund, as applicable.

Valuations of derivative instruments are carried out daily, using normal exchange reporting sources for exchange-traded derivatives and specific broker enquiry for over-the-counter derivatives.

The value of forward contracts is the gain or loss that would be realized if, on the valuation date, the positions were to be closed out. The change in value of forward contracts is included in the Statement of Comprehensive Income – Other changes in fair value of investments and other net assets – Net unrealized gain (loss).

The daily fluctuation of futures contracts or swaps, along with daily cash settlements made by the Fund, where applicable, are equal to the change in unrealized gains or losses that are best determined at the settlement price. These unrealized gains or losses are recorded and reported as such until the Fund closes out the contract or the contract expires. Margin paid or deposited in respect of futures contracts or swaps is reflected as a receivable in the Statement of Financial Position – Margin on derivatives. Any change in the variation margin requirement is settled daily.

Premiums paid for purchasing an option are recorded in the Statement of Financial Position – Investments at fair value.

Premiums received from writing options are included in the Statement of Financial Position as a liability and subsequently adjusted daily to fair value. If a written option expires unexercised, the premium received is recognized as a realized gain. If a written call option is exercised, the difference between the proceeds of the sale plus the value of the premium, and the cost of the security is recognized as a realized gain or loss. If a written put option is exercised, the cost of the security acquired is the exercise price of the option less the premium received.

Refer to the Schedule of Derivative Instruments and Schedule of Options Purchased/Written, as applicable, included in the Schedule of Investments for a listing of derivative and options positions as at March 31, 2024.

The Fund categorizes the fair value of its assets and liabilities into three categories, which are differentiated based on the observable nature of the inputs and extent of estimation required.

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Examples of Level 2 valuations include quoted prices for similar securities, quoted prices on inactive markets and from recognized investment dealers, and the application of factors derived from observable data to non-North American quoted prices in order to estimate the impact of differences in market closing times.

Financial instruments classified as Level 2 investments are valued based on the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Short-term investments classified as Level 2 investments are valued based on amortized cost plus accrued interest which closely approximates fair value.

The estimated fair values for these securities may be different from the values that would have been used had a ready market for the investment existed; and Level 3 – Inputs that are not based on observable market data.

The inputs are considered observable if they are developed using market data, such as publicly available information about actual events or transactions, and that reflect the assumption that market participants would use when pricing the asset or liability.

See Note 10 for the fair value classifications of the Fund.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(c) Income recognition

Interest income for distribution purposes represents the coupon interest received by the Fund which is accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds, which are amortized on a straight-line basis. Dividends are accrued as of the ex-dividend date. Unrealized gains or losses on investments, realized gains or losses on the sale of investments, including foreign exchange gains or losses on such investments, are calculated on a weighted average cost basis. Distributions received from an underlying fund are included in interest income, dividend income, realized gains (losses) on sale of investments or fee rebate income, as appropriate, on the ex-dividend or distribution date.

Income, realized gains (losses) and unrealized gains (losses) are allocated daily among the series on a pro-rata basis.

(d) Securities lending and repurchase transactions

The Fund is permitted to enter into securities lending, repurchase and reverse repurchase transactions as set out in the Fund's Simplified Prospectus. These transactions involve the temporary exchange of securities for collateral with a commitment to redeliver the same securities on a future date.

Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on cash or securities held as collateral. Income earned from these transactions is included in the Statement of Comprehensive Income and recognized when earned. Securities lending transactions are administered by The Bank of New York Mellon (the "Securities Lending Agent"). The value of cash or securities held as collateral must be at least 102% of the fair value of the securities loaned, sold or purchased.

Note 10 summarizes the details of securities loaned and collateral received as at the end of period, as well as a reconciliation of securities lending income during the period, if applicable. Collateral received is comprised of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments, and financial institutions.

(e) Commissions and other portfolio transaction costs

Commissions and other portfolio transaction costs are costs incurred to acquire, issue or dispose of financial assets or liabilities. They include fees and commissions paid to agents, exchanges, brokers, dealers and other intermediaries. The total brokerage commissions incurred by the Fund in connection with portfolio transactions for the periods, together with other transaction charges, is disclosed in the Statement of Comprehensive Income. Brokerage business is allocated to brokers based on the best net result for the Fund. Subject to this criteria, commissions may be paid to brokerage firms which provide (or pay for) certain services, other than order execution, which may include investment research, analysis and reports, and databases or software in support of these services. Where applicable and ascertainable, the value of these services generated during the periods is disclosed in Note 10. The value of certain proprietary services provided by brokers cannot be reasonably estimated.

(f) Increase (decrease) in net assets attributable to securityholders from operations per security

Increase (decrease) in net assets attributable to securityholders from operations per security in the Statement of Comprehensive Income represents the increase (decrease) in net assets attributable to securityholders from operations for the period, divided by the weighted average number of securities outstanding during the period.

(g) Currency

The functional and presentation currency of the Fund is Canadian dollars. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated to Canadian dollars at the rate of exchange prevailing at the time of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statement of Comprehensive Income – Net realized gain (loss).

The fair value of investments and other assets and liabilities, denominated in foreign currencies, are translated to Canadian dollars at the rate of exchange prevailing on each business day.

(h) Offsetting

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position only when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously. In the normal course of business, the Fund enters into various master netting agreements or similar agreements that do not meet the criteria for offsetting in the Statement of Financial Position but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or termination of the contracts. Note 10 summarizes the details of such offsetting, if applicable, subject to master netting arrangements or other similar agreements and the net impact to the Statement of Financial Position if all such rights were exercised.

Income and expenses are not offset in the Statement of Comprehensive Income unless required or permitted to by an accounting standard, as specifically disclosed in the IFRS policies of the Fund.

(i) Net assets attributable to securityholders per security

Net assets attributable to securityholders per security is computed by dividing the net assets attributable to securityholders of a series of securities on a business day by the total number of securities of the series outstanding on that day.

(j) Net asset value per security

The daily Net Asset Value ("NAV") of an investment fund may be calculated without reference to IFRS as per the Canadian Securities Administrators' ("CSA") regulations. The difference between NAV and Net assets attributable to securityholders (as reported in the financial statements), if any, is mainly due to differences in fair value of investments and other financial assets and liabilities and is disclosed in Note 10.

(k) Mergers

In a fund merger, the Fund acquires all of the assets and assumes all of the liabilities of the terminating fund at fair value in exchange for securities of the Fund on the effective date of the merger.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(l) Future accounting changes

The Fund has determined there are no material implications to the Fund's financial statements arising from IFRS issued but not yet effective.

4. Critical Accounting Estimates and Judgments

The preparation of these financial statements requires management to make estimates and assumptions that primarily affect the valuation of investments. Estimates and assumptions are reviewed on an ongoing basis. Actual results may differ from these estimates.

The following discusses the most significant accounting judgments and estimates made in preparing the financial statements:

Use of Estimates

Fair value of securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets and are valued using valuation techniques that make use of observable data, to the extent practicable. Various valuation techniques are utilized, depending on a number of factors, including comparison with similar instruments for which observable market prices exist and recent arm's length market transactions. Key inputs and assumptions used are company specific and may include estimated discount rates and expected price volatilities. Changes in key inputs, could affect the reported fair value of these financial instruments held by the Fund.

Use of Judgements

Classification and measurement of investments

In classifying and measuring financial instruments held by the Fund, the Manager is required to make significant judgments in order to determine the most appropriate classification in accordance with IFRS 9. The Manager has assessed the Fund's business model, the manner in which all financial instruments are managed and performance evaluated as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate measurement and presentation of the Fund's financial instruments.

Functional currency

The Fund's functional and presentation currency is the Canadian dollar, which is the currency considered to best represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration the manner in which securities are issued and redeemed and how returns and performance by the Fund are measured.

Interest in unconsolidated structured entities

In determining whether an unlisted open-ended investment fund or an exchange-traded fund in which the Fund invests ("Underlying Funds"), but that it does not consolidate, meets the definition of a structured entity, the Manager is required to make significant judgments about whether these underlying funds have the typical characteristics of a structured entity. These Underlying Funds do meet the definition of a structured entity because:

- I. The voting rights in the Underlying Funds are not dominant factors in deciding who controls them;
- II. the activities of the Underlying Funds are restricted by their offering documents; and
- III. the Underlying Funds have narrow and well-defined investment objectives to provide investment opportunities for investors while passing on the associated risks and rewards.

As a result, such investments are accounted for at FVTPL. Note 10 summarizes the details of the Fund's interest in these Underlying Funds, if applicable.

5. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and, accordingly, is subject to tax on its income including net realized capital gains in the taxation year, which is not paid or payable to its securityholders as at the end of the taxation year. The Fund maintains a December year-end for tax purposes. The Fund may be subject to withholding taxes on foreign income. In general, the Fund treats withholding tax as a charge against income for tax purposes. The Fund will distribute sufficient amounts from net income for tax purposes, as required, so that the Fund will not pay income taxes other than refundable tax on capital gains, if applicable.

Losses of the Fund cannot be allocated to investors and are retained in the Fund for use in future years. Non-capital losses may be carried forward up to 20 years to reduce taxable income and realized capital gains of future years. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Refer to Note 10 for the Fund's loss carryforwards.

6. Management Fees and Other Expenses

- (a) Each series of the Fund will incur expenses that can be specifically attributed to that series. Common expenses of the Fund are allocated across the series of the Fund on a pro rata basis.
- (b) The Manager provides or arranges for the provision of investment and advisory services for a management fee. See Note 10 for the annual rates paid (as a percent of average assets) by the Fund.
- (c) The Fund pays the Manager an administration fee and in return the Manager will bear the operating expenses of the Fund, other than certain specified costs. See Note 10 for the annual rates paid (as a percent of average assets) by the Fund.

Other Fund costs include taxes (including but not limited to GST/HST and income tax), transaction costs related to the purchase and sale of investments and derivatives, interest and borrowing costs, and Independent Review Committee ("IRC") costs.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

6. Management Fees and Other Expenses (cont'd)

- (d) The Fund may pay the Distributors a service fee to compensate them for providing or arranging for the provision of services to the Fund. A portion of the service fee related to Series C and Tc is rebated by the Distributors to the Fund on a quarterly basis as outlined in the Fund's Prospectus. The rebate is distributed as a capital distribution to eligible securityholders and is reinvested in additional Series C or Tc securities of the Fund or another distributing fund held by the securityholder. See Note 10 for the annual rates paid (as a percent of average assets) by the Fund.
- (e) The Trustee is responsible for overall direction and management of the affairs of the Fund. See Note 10 for the annual rates paid (as a percent of average assets) to the Trustee by the Fund.
- (f) An advisory fee is charged by the Distributors for investment advice and administrative services related to Series U and Tu, if issued. The advisory fee is payable monthly directly by investors in Series U and Tu, and not by the Fund.
- (g) GST/HST paid by the Fund on its expenses is not recoverable. In these financial statements, reference to GST/HST includes QST (Quebec sales tax), as applicable.
- (h) Other expenses are comprised of interest and borrowing charges and other miscellaneous expenses.
- (i) The Manager may, at its discretion, pay certain expenses of the Fund so that the Fund's performance remains competitive; however, there is no assurance that this will occur in the future. Any expenses absorbed by the Manager during the periods have been reported in the Statements of Comprehensive Income.
- (j) Investment, if any, in Underlying Funds will be in series that do not pay fees. The ETFs into which the Fund may invest may have their own fees and expenses which reduce the value of the ETF. Generally, the Manager has determined that fees paid by an ETF are not duplicative with the fees paid by the Fund. However, where the ETF is managed by Mackenzie Financial Corporation, the ETF may distribute a fee rebate to the Fund to offset fees paid within the ETF. There is no assurance that these distributions will continue in the future.
- (k) Agreements between the individual members of the Fund's IRC and the Trustee, on behalf of the Fund, provides for the indemnification of each IRC member by the Fund from and against liabilities and costs in respect of any action or suit against the member by reason of being or having been a member of the IRC, provided that the member acted honestly and in good faith with a view to the best interest of the Fund, or, in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, that they had reasonable grounds for believing that his/her conduct was lawful. No claims with respect to such occurrences have been made and, as such, no amount has been recorded in these financial statements with respect to these indemnifications.

7. Fund's Capital

The capital of the Fund, which is comprised of the net assets attributable to securityholders, is divided into different series with each series having an unlimited number of securities. The securities outstanding for the Fund as at March 31, 2024 and 2023 and securities issued, reinvested and redeemed for the periods are presented in the Statement of Changes in Financial Position. The Manager manages the capital of the Fund in accordance with the investment objectives as discussed in Note 10.

8. Financial Instruments Risk

(a) Risk management

The Fund's investment activities expose it to a variety of financial risks, as defined in IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"). The Fund's exposure to financial risks is concentrated in its investments, which are presented in the Schedule of Investments, as at March 31, 2024, grouped by asset type, with geographic and sector information.

The Manager seeks to minimize potential adverse effects of financial instrument risks on the Fund's performance by employing professional, experienced portfolio advisors, daily monitoring of the Fund's positions and market events, and diversifying the investment portfolio within the constraints of the investment objective. To assist in managing risk, the Manager also uses internal guidelines that identify the target exposures for each type of risk, maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy, internal guidelines and securities regulations.

(b) Liquidity risk

Liquidity risk arises when the Fund encounters difficulty in meeting its financial obligations as they become due. The Fund is exposed to liquidity risk due to potential daily cash redemptions of redeemable securities. In order to monitor the liquidity of its assets, the Fund utilizes a liquidity risk management program that calculates the number of days to convert the investments held by the Fund into cash using a multi-day liquidation approach. This liquidity risk analysis assesses the Fund's liquidity against predetermined minimum liquidity percentages, established for different time periods, and is monitored quarterly. In addition, the Fund has the ability to borrow up to 5% of its net assets for the purposes of funding redemptions. In order to comply with securities regulations, the Fund must maintain at least 85% of its assets in liquid investments (i.e., investments that can be readily sold).

(c) Currency risk

Currency risk is the risk that financial instruments which are denominated or exchanged in a currency other than the Canadian dollar, which is the Fund's functional currency, will fluctuate due to changes in exchange rates. Generally, foreign denominated investments increase in value when the value of the Canadian dollar (relative to foreign currencies) falls. Conversely, when the value of the Canadian dollar rises relative to foreign currencies, the values of foreign denominated investments fall.

Note 10 indicates the foreign currencies, if applicable, to which the Fund had significant exposure, including both monetary and non-monetary financial instruments, and illustrates the potential impact, in Canadian dollar terms, to the Fund's net assets had the Canadian dollar strengthened or weakened by 5% relative to all foreign currencies, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to currency risk illustrated in Note 10 includes potential indirect impacts from Underlying Funds and ETFs in which the Fund invests, and/or derivative contracts including forward currency contracts. Other financial assets and liabilities (including dividends and interest receivable, and receivables/payables for investments sold/purchased) that are denominated in foreign currencies do not expose the Fund to significant currency risk.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

8. Financial Instruments Risk (cont'd)

(d) Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The Fund is exposed to the risk that the value of interest-bearing financial instruments will fluctuate due to changes in the prevailing levels of market interest rates. Generally, these securities increase in value when interest rates fall and decrease in value when interest rates rise.

If significant, Note 10 summarizes the Fund's interest-bearing financial instruments by remaining term to maturity and illustrates the potential impact to the Fund's net assets had prevailing interest rates increased or decreased by 1%, assuming a parallel shift in the yield curve, all other variables held constant.

The Fund's sensitivity to interest rate changes was estimated using weighted average duration, and a valuation model that estimates the impact to the fair value of mortgages based on changes in prevailing interest rates in a manner consistent with the valuation policy for mortgages. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to interest rate risk illustrated in Note 10 includes potential indirect impacts from Underlying Funds and ETFs in which the Fund invests, and/or derivative contracts. Cash and cash equivalents and other money market instruments are short term in nature and are not generally subject to significant amounts of interest rate risk.

(e) Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund. Note 10 summarizes the Fund's exposure, if applicable and significant, to credit risk. If presented, credit ratings and rating categories are based on ratings issued by a designated rating organization. Indirect exposure to credit risk may arise from fixed-income securities, such as bonds, held by the Underlying Funds and ETFs, if any. The fair value of debt securities includes consideration of the creditworthiness of the debt issuer.

To minimize the possibility of settlement default, securities are exchanged for payment simultaneously, where market practices permit, through the facilities of a central depository and/or clearing agency where customary. The carrying amount of investments and other assets represents the maximum credit risk exposure as at the date of the Statement of Financial Position.

The Fund may enter into securities lending transactions with counterparties and it may also be exposed to credit risk from the counterparties to the derivative instruments it may use. Credit risk associated with these transactions is considered minimal as all counterparties have a rating equivalent to a designated rating organization's credit rating of not less than A-1 (low) on their short-term debt and of A on their long-term debt, as applicable.

(f) Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer or other factors affecting all instruments traded in a market or market segment. All investments present a risk of loss of capital. The Manager manages this risk through a careful selection of securities and other financial instruments within the parameters of the investment strategies. Except for certain derivative contracts, the maximum risk resulting from financial instruments is equivalent to their fair value. The maximum risk of loss on certain derivative contracts such as forwards, swaps and futures contracts is equal to their notional values. In the case of written call (put) options and futures contracts sold short, the maximum loss to the Fund increases, theoretically without limit, as the fair value of the underlying security increases (decreases). However, these instruments are generally used within the overall investment management process to manage the risk from the underlying investments and do not typically increase the overall risk of loss to the Fund. This risk is mitigated by ensuring that the Fund holds a combination of the underlying interest, cash cover and/or margin that is equal to or greater than the value of the derivative contract.

Other price risk typically arises from exposure to equity and commodity securities. If significant, Note 10 illustrates the potential increase or decrease in the Fund's net assets, had the prices on the respective exchanges for these securities increased or decreased by 10%, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to other price risk illustrated in Note 10 includes potential indirect impacts from Underlying Funds and ETFs in which the Fund invests, and/or derivative contracts.

In addition, if the Fund invests in IG Mackenzie Real Property Fund, the Fund is exposed to the risk that the value of the Underlying Fund could change as a result of changes in the valuation of real properties. Valuations of real properties are sensitive to changes in capitalization rates. Note 10 also indicates the Fund's sensitivity, if any, to a 25 basis point change in the weighted average capitalization rates.

(g) Underlying funds

The Fund may invest in underlying funds and may be indirectly exposed to currency risk, interest rate risk, other price risk and credit risk from fluctuations in the value of financial instruments held by the underlying funds. Note 10 summarizes the Fund's exposure, if applicable and significant, to these risks from underlying funds.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

9. Other Information

(a) Abbreviations

Foreign currencies, if any, are presented in these financial statements using the following abbreviated currency codes:

Currency Code	Description	Currency Code	Description	Currency Code	Description
AUD	Australian dollars	HUF	Hungarian forint	PEN	Peruvian nuevo sol
BRL	Brazilian real	IDR	Indonesian rupiah	PHP	Philippine peso
CAD	Canadian dollars	ILS	Israeli sheqel	PLN	Polish zloty
CHF	Swiss franc	INR	Indian rupee	RON	Romanian leu
CZK	Czech koruna	JPY	Japanese yen	RUB	Russian ruble
CLP	Chilean peso	KOR	South Korean won	SEK	Swedish krona
CNY	Chinese yuan	MXN	Mexican peso	SGD	Singapore dollars
COP	Colombian peso	MYR	Malaysian ringgit	THB	Thailand baht
DKK	Danish krone	NGN	Nigerian naira	TRL	Turkish lira
EUR	Euro	NOK	Norwegian krona	USD	United States dollars
GBP	United Kingdom pounds	NTD	New Taiwan dollar	ZAR	South African rand
HKD	Hong Kong dollars	NZD	New Zealand dollars	ZMW	Zambian kwacha

(b) Additional information available

A copy of the Fund's current Simplified Prospectus, Annual Information Form and/or Management Report of Fund Performance, will be provided, without charge, by writing to: Investors Group Financial Services Inc., 447 Portage Avenue, Winnipeg, Manitoba, R3B 3H5 or, in Quebec, 2001, Robert-Bourassa Boulevard, Bureau 2000, Montreal, Quebec, H3A 2A6, or by calling toll-free 1-888-746-6344 (in Quebec 1-800-661-4578), or by visiting the IG Wealth Management website at www.ig.ca or SEDAR+ at www.sedarplus.ca. Copies of financial statements for all IG Wealth Management Funds are also available upon request or by visiting the IG Wealth Management website at www.ig.ca or SEDAR+ at www.sedarplus.ca.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a))

(a) Fund Formation, Series Information and Fund Merger

Date of Formation: February 27, 2023

Series	Inception/ Reinstatement Date	Management fee (%)	Service fee (%)	Administration fee (%)	Trustee fee (%)
Series A	October 24, 2002	1.95	0.30	0.18	0.05
Series B	October 24, 2002	1.95	0.30	0.18	0.05
Series F	July 12, 2013	0.85	–	0.18	0.05
Series J DSC	July 13, 2012	1.70	0.30	0.18	0.05
Series J NL	July 13, 2012	1.70	0.30	0.18	0.05

The fee rates in the table above are rounded to two decimals.

These are the inception dates of the applicable series of the Predecessor Fund.

Until June 28, 2022, the annual management fee rates were as follows: Series A and B: 2.00%; Series F: 0.90%; Series J DSC and J NL: 1.75%.

Effective May 3, 2024, Series A was redesignated as Series B; and effective May 10, 2024, Series J DSC was redesignated as Series J NL.

Series A and J DSC are closed to new investments by securityholders, but still available for reinvested distributions and switches from corresponding series of other IG Wealth Management Funds.

The Manager has engaged Mackenzie Financial Corporation as sub-advisor to assist in investment management and trade execution for the Fund.

On February 16, 2023, the IG Wealth Management Funds Independent Review Committee approved a proposal to wind up Investors Group Corporate Class Inc. because it was in a taxable position. As a result of this wind-up, the IG Mackenzie Global Health Care Class (the "Predecessor Fund") merged into the Fund, an equivalent trust fund that has a substantially similar investment objective to that of the Predecessor Fund and is managed by the same sub-advisor. This merger took place on a tax deferred basis on May 19, 2023. The merger was effected by transferring the net assets of the Predecessor Fund in exchange for the securities of the Fund at fair market value. Series A, Series B, Series F, Series J DSC and Series J NL of the Predecessor Fund were issued 732 Series A securities, 453 Series B securities, 9,880 Series F securities, 298 Series J DSC securities, and 162 Series J NL securities of the Fund in exchange for net assets of \$324,898, which was the fair value on May 19, 2023.

Following the merger, the Predecessor Fund was terminated. The Manager paid the expenses incurred to effect the merger.

The comparative figures presented in these financial statements represent the net assets, results of operations, changes in net assets, cash flows and increase (decrease) in fund securities of the Predecessor Fund. Similarly, the results of operations, changes in net assets, cash flows and increase (decrease) in fund securities of the Predecessor Fund for the period from April 1, 2023 to May 19, 2023 have been included in the current period of these financial statements.

(b) Tax Loss Carryforwards

As at the last taxation year-end, there were no capital and non-capital losses available to carry forward for tax purposes.

(c) Securities Lending

	March 31, 2024		March 31, 2023	
	(\$)		(\$)	
Value of securities loaned	3,234		4,981	
Value of collateral received	3,422		5,380	

	March 31, 2024		March 31, 2023	
	(\$)	(%)	(\$)	(%)
Gross securities lending income	1	100.0	17	100.0
Tax withheld	–	–	–	–
	1	100.0	17	100.0
Payments to securities lending agent	–	–	(3)	(17.6)
Securities lending income	1	100.0	14	82.4

(d) Commissions

	(\$)
March 31, 2024	145
March 31, 2023	70

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a)) (cont'd)

(e) Risks Associated with Financial Instruments

i. Risk exposure and management

The Fund aims to provide long-term capital growth by investing in the common shares of global corporations engaged in the development, production or distribution of products and services related to the treatment or prevention of medical diseases or other medical related problems.

ii. Currency risk

The tables below summarize the Fund's exposure to currency risk.

March 31, 2024								
Currency	Investments (\$)	Cash and Cash Equivalents (\$)	Derivative Instruments (\$)	Net Exposure (\$)	Impact on net assets			
					Strengthened by 5%		Weakened by 5%	
					(\$)	%	(\$)	%
USD	250,739	874	–	251,613				
CHF	20,745	–	–	20,745				
JPY	17,160	27	–	17,187				
GBP	16,681	–	–	16,681				
DKK	15,546	–	–	15,546				
EUR	6,348	–	–	6,348				
AUD	1,638	–	–	1,638				
SEK	340	–	–	340				
Total	329,197	901	–	330,098				
% of Net Assets	98.8	0.3	–	99.1				
Total currency rate sensitivity					(16,505)	(5.0)	16,505	5.0

March 31, 2023								
Currency	Investments (\$)	Cash and Cash Equivalents (\$)	Derivative Instruments (\$)	Net Exposure (\$)	Impact on net assets			
					Strengthened by 5%		Weakened by 5%	
					(\$)	%	(\$)	%
USD	227,259	384	–	227,643				
CHF	22,317	–	–	22,317				
EUR	18,351	6	–	18,357				
GBP	16,391	–	–	16,391				
DKK	15,954	–	–	15,954				
JPY	14,940	–	–	14,940				
AUD	2,959	–	–	2,959				
SEK	949	–	–	949				
Total	319,120	390	–	319,510				
% of net assets	99.5	0.1	–	99.6				
Total currency rate sensitivity					(15,976)	(5.0)	15,976	5.0

iii. Interest rate risk

As at March 31, 2024 and 2023, the Fund did not have a significant exposure to interest rate risk.

iv. Other price risk

The table below summarizes the Fund's exposure to other price risk.

Impact on net assets	Increased by 10%		Decreased by 10%	
	(\$)	(%)	(\$)	(%)
March 31, 2024	33,090	9.9	(33,090)	(9.9)
March 31, 2023	31,952	10.0	(31,952)	(10.0)

v. Credit risk

As at March 31, 2024 and 2023, the Fund did not have a significant exposure to credit risk.

IG MACKENZIE GLOBAL HEALTH CARE FUND

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information *(in '000, except for (a)) (cont'd)*

(f) Fair Value Classification

The table below summarizes the fair value of the Fund's financial instruments using the fair value hierarchy described in note 3.

	March 31, 2024				March 31, 2023			
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)
Equities	327,590	–	–	327,590	227,143	91,861	–	319,004
Exchange Traded Funds	3,306	–	–	3,306	516	–	–	516
Total	330,896	–	–	330,896	227,659	91,861	–	319,520

The Fund's policy is to recognize transfers into and transfers out of fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer.

During the period ended March 31, 2024, non-North American equities frequently transferred between Level 1 (unadjusted quoted market prices) and Level 2 (adjusted market prices). As at March 31, 2024, these securities were classified as Level 1 (2023 – Level 2).

(g) Manager's Investment in the Fund

As at March 31, 2024 and 2023, there were no investments by the Manager in the Fund.

(h) Offsetting of Financial Assets and Liabilities

As at March 31, 2024 and 2023, there were no amounts subject to offsetting.

(i) Interest in Unconsolidated Structured Entities

The Fund's investment details in the Underlying Funds as at March 31, 2024 and 2023 are as follows:

March 31, 2024	% of Underlying Fund's Net Assets	Fair Value of Fund's Investment (\$)
Health Care Select Sector SPDR Fund	0.0	3,306

March 31, 2023	% of Underlying Fund's Net Assets	Fair Value of Fund's Investment (\$)
Health Care Select Sector SPDR Fund	0.0	516